Literature DB >> 19042123

Current perspective - trastuzumab.

Peter S Hall1, David A Cameron.   

Abstract

This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19042123     DOI： 10.1016/j.ejca.2008.10.013

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  17 in total

Review 1.  Therapeutic proteins.

Authors:  Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

2.  Therapeutic antibodies, vaccines and antibodyomes.

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-14       Impact factor: 5.857

Review 3.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

4.  Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions.

Authors:  Feng Xu; Alexander Sunderland; Yue Zhou; Richard D Schulick; Barish H Edil; Yuwen Zhu
Journal:  Cancer Immunol Immunother       Date:  2017-06-16       Impact factor: 6.968

5.  Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.

Authors:  Peter S Hall; Claire Hulme; Christopher McCabe; Yemi Oluboyede; Jeff Round; David A Cameron
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.981

Review 6.  Therapeutic antibodies against cancer.

Authors:  Mark J Adler; Dimiter S Dimitrov
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

Review 7.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

8.  Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Authors:  Holbrook E Kohrt; Roch Houot; Kipp Weiskopf; Matthew J Goldstein; Ferenc Scheeren; Debra Czerwinski; A Dimitrios Colevas; Wen-Kai Weng; Michael F Clarke; Robert W Carlson; Frank E Stockdale; Joseph A Mollick; Lieping Chen; Ronald Levy
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

9.  Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma.

Authors:  M Watanabe; K Kono; Y Kawaguchi; Y Mizukami; K Mimura; T Maruyama; H Fujii
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

Review 10.  Immunotherapy of cancer in 2012.

Authors:  John M Kirkwood; Lisa H Butterfield; Ahmad A Tarhini; Hassane Zarour; Pawel Kalinski; Soldano Ferrone
Journal:  CA Cancer J Clin       Date:  2012-05-10       Impact factor: 508.702
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.